BLASUBCUTANEOUSSYRINGE
Approved
Jan 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
29
Data completeness
4/8 — Partial
NEULASTA (pegfilgrastim) by Amgen. Approved for leukocyte growth factor [epc]. First approved in 2002.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEULASTA is a pegylated granulocyte colony-stimulating factor (G-CSF) cytokine developed by Amgen, approved in 2002 as a syringe injection. It works by binding to cell surface receptors on hematopoietic cells to stimulate proliferation, differentiation, and functional activation. The drug is indicated to decrease the incidence of infection manifested by febrile neutropenia in patients receiving myelosuppressive chemotherapy.
$0.0BPart D
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (29)
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
Started Apr 2025
18 enrolled
Preeclampsia
Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults
Started Apr 2025
180 enrolled
Healthy Volunteer
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
Started Mar 2025
18 enrolled
Preeclampsia
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
Started Nov 2023
100 enrolled
Breast Neoplasms
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Started Dec 2021
17 enrolled
Multiple Myeloma
Worked on NEULASTA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.